BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lattenist L, Lechner SM, Messaoudi S, Le Mercier A, El Moghrabi S, Prince S, Bobadilla NA, Kolkhof P, Jaisser F, Barrera-Chimal J. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress. Hypertension. 2017;69:870-878. [PMID: 28320854 DOI: 10.1161/hypertensionaha.116.08526] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Kolkhof P, Lawatscheck R, Filippatos G, Bakris GL. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems. IJMS 2022;23:9243. [DOI: 10.3390/ijms23169243] [Reference Citation Analysis]
2 DeFronzo RA, Bakris GL. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes Obes Metab 2022;24:1197-205. [PMID: 35302284 DOI: 10.1111/dom.14696] [Reference Citation Analysis]
3 Barrera-Chimal J, Gerarduzzi C, Rossignol P, Jaisser F. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. Clin Sci (Lond) 2022;136:1005-17. [PMID: 35765983 DOI: 10.1042/CS20220212] [Reference Citation Analysis]
4 Mima A. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches. Adv Ther 2022. [PMID: 35751762 DOI: 10.1007/s12325-022-02223-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Nakamura T, Girerd S, Jaisser F, Barrera-chimal J. Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease. Kidney International Supplements 2022;12:12-8. [DOI: 10.1016/j.kisu.2021.11.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
6 Zhang MZ, Bao W, Zheng QY, Wang YH, Sun LY. Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol 2022;13:819327. [PMID: 35197856 DOI: 10.3389/fphar.2022.819327] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Luan ZL, Zhang C, Ming WH, Huang YZ, Guan YF, Zhang XY. Nuclear receptors in renal health and disease. EBioMedicine 2022;76:103855. [PMID: 35123268 DOI: 10.1016/j.ebiom.2022.103855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kawanami D, Takashi Y, Muta Y, Oda N, Nagata D, Takahashi H, Tanabe M. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. Front Pharmacol 2021;12:754239. [PMID: 34790127 DOI: 10.3389/fphar.2021.754239] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Droebner K, Pavkovic M, Grundmann M, Hartmann E, Goea L, Nordlohne J, Klar J, Eitner F, Kolkhof P. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis. Am J Nephrol 2021;52:588-601. [PMID: 34515038 DOI: 10.1159/000518254] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
10 Piani F, Reinicke T, Borghi C, Tommerdahl KL, Cara-Fuentes G, Johnson RJ, Bjornstad P. Acute Kidney Injury in Pediatric Diabetic Kidney Disease. Front Pediatr 2021;9:668033. [PMID: 34211943 DOI: 10.3389/fped.2021.668033] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Vodošek Hojs N, Bevc S, Ekart R, Piko N, Petreski T, Hojs R. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. Pharmaceuticals (Basel) 2021;14:561. [PMID: 34208285 DOI: 10.3390/ph14060561] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
12 Veneti S, Tziomalos K. The Role of Finerenone in the Management of Diabetic Nephropathy. Diabetes Ther 2021;12:1791-7. [PMID: 34050896 DOI: 10.1007/s13300-021-01085-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 2021;42:152-61. [PMID: 33099609 DOI: 10.1093/eurheartj/ehaa736] [Cited by in Crossref: 24] [Cited by in F6Publishing: 68] [Article Influence: 24.0] [Reference Citation Analysis]
14 Bădilă E, Japie C, Weiss E, Balahura AM, Bartoș D, Scafa Udriște A. The Road to Better Management in Resistant Hypertension-Diagnostic and Therapeutic Insights. Pharmaceutics 2021;13:714. [PMID: 34068168 DOI: 10.3390/pharmaceutics13050714] [Reference Citation Analysis]
15 Epstein M. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present. Am J Nephrol 2021;52:209-16. [PMID: 33857953 DOI: 10.1159/000515622] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
16 Lefranc C, Friederich-Persson M, Foufelle F, Nguyen Dinh Cat A, Jaisser F. Adipocyte-Mineralocorticoid Receptor Alters Mitochondrial Quality Control Leading to Mitochondrial Dysfunction and Senescence of Visceral Adipose Tissue. Int J Mol Sci 2021;22:2881. [PMID: 33809055 DOI: 10.3390/ijms22062881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL; FIDELIO-DKD Investigators. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation 2021;143:540-52. [PMID: 33198491 DOI: 10.1161/CIRCULATIONAHA.120.051898] [Cited by in Crossref: 26] [Cited by in F6Publishing: 70] [Article Influence: 13.0] [Reference Citation Analysis]
18 Pazos F. Range of adiposity and cardiorenal syndrome. World J Diabetes 2020; 11(8): 322-350 [PMID: 32864046 DOI: 10.4239/wjd.v11.i8.322] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
19 Barrera-Chimal J, Jaisser F. Vascular and inflammatory mineralocorticoid receptors in kidney disease. Acta Physiol (Oxf) 2020;228:e13390. [PMID: 31529757 DOI: 10.1111/apha.13390] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
20 Sharifi F, Reisi P, Malek M. Synaptic plasticity in hippocampal CA1 neurons and learning behavior in acute kidney injury, and estradiol replacement in ovariectomized rats. BMC Neurosci 2019;20:52. [PMID: 31585527 DOI: 10.1186/s12868-019-0534-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
21 Schlader ZJ, Hostler D, Parker MD, Pryor RR, Lohr JW, Johnson BD, Chapman CL. The Potential for Renal Injury Elicited by Physical Work in the Heat. Nutrients 2019;11:E2087. [PMID: 31487794 DOI: 10.3390/nu11092087] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
22 Capelli I, Gasperoni L, Ruggeri M, Donati G, Baraldi O, Sorrenti G, Caletti MT, Aiello V, Cianciolo G, La Manna G. New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure. J Nephrol 2020;33:37-48. [PMID: 30989614 DOI: 10.1007/s40620-019-00600-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 29] [Article Influence: 6.7] [Reference Citation Analysis]
23 Qin J, Peng ZZ, Li Q, Wen R, Tao LJ. Renal Fibrosis and Mitochondrial Damage. Chin Med J (Engl) 2018;131:2769-72. [PMID: 30425211 DOI: 10.4103/0366-6999.245272] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
24 Lytvyn Y, Godoy LC, Scholtes RA, van Raalte DH, Cherney DZ. Mineralocorticoid Antagonism and Diabetic Kidney Disease. Curr Diab Rep 2019;19:4. [PMID: 30673886 DOI: 10.1007/s11892-019-1123-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
25 Girerd S, Frimat L, Ducloux D, Le Meur Y, Mariat C, Moulin B, Mousson C, Rieu P, Dali-Youcef N, Merckle L, Lepage X, Rossignol P, Girerd N, Jaisser F. EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial. Trials 2018;19:595. [PMID: 30376884 DOI: 10.1186/s13063-018-2956-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
26 González-Blázquez R, Somoza B, Gil-Ortega M, Martín Ramos M, Ramiro-Cortijo D, Vega-Martín E, Schulz A, Ruilope LM, Kolkhof P, Kreutz R, Fernández-Alfonso MS. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol 2018;9:1131. [PMID: 30356804 DOI: 10.3389/fphar.2018.01131] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
27 Davis J, Oparil S. Novel Medical Treatments for Hypertension and Related Comorbidities. Curr Hypertens Rep 2018;20:90. [PMID: 30145617 DOI: 10.1007/s11906-018-0890-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
28 Davel AP, Jaffe IZ, Tostes RC, Jaisser F, Belin de Chantemèle EJ. New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects. Am J Physiol Heart Circ Physiol 2018;315:H989-99. [PMID: 29957022 DOI: 10.1152/ajpheart.00073.2018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
29 DuPont JJ, Jaffe IZ. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The role of the mineralocorticoid receptor in the vasculature. J Endocrinol 2017;234:T67-82. [PMID: 28634267 DOI: 10.1530/JOE-17-0009] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 10.8] [Reference Citation Analysis]